Skip to main contentPsst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveFree Webinar — Wednesday, September 2 at 2:00 PM EDT

Register Free →

Vehicle Recompete: Idc 75N95022D00017

Active
Federal

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

AI Contract Overview

Show more

This contract is an indefinite delivery contract vehicle (IDC) with the identifier 75N95022D00017, overseeing the ordering period from September 5, 2022, through September 4, 2027. It supports the National Institute on Drug Abuse (NIDA) data, statistics, and clinical trial operations under the Department of Health and Human Services, managed by the National Institutes of Health (NIH). The contract has a ceiling value of approximately $44.3 million and does not involve any set-aside provisions. It represents a full recompete classification, indicating a competitive solicitation process to award the contract. Currently, there are no active task orders valued at zero, but several significant task orders have been executed under this vehicle. Several key task orders highlight the contract’s scope and value, all awarded to The Emmes Company, LLC. These task orders cover a variety of research and analytical services, including the management and support of the Data and Statistics Center (DSC) from March 2025 to February 2026 ($1.85 million), data analysis related to GLP-1 as an adjunct to buprenorphine from May 2025 to February 2028 ($1.4 million), and various other clinical and secondary analysis projects concerning opioid use disorder and related research, with task order values ranging from approximately $375,000 to $800,000. The work performed under these task orders reflects a comprehensive support framework for clinical trials and data management activities essential to advancing research efforts around drug abuse and treatment strategies.

General Info

Indefinite delivery contract supporting NIDA clinical trial data, totaling $44.3 million, awarded to Emmes.

Agency

Department Of Health And Human Services → National Institutes Of Health NidaView Agency

NAICS

541715 - Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)View NAICS

Place of Performance

Not specified

Set-Aside

NONE

Documents

(0)

No documents available

AI Contract Breakdown

Uniform Contract Format

No contract breakdown available.

Cannot generate Contract Breakdown because no documents were found from this contract's source.

Timeline

Posted

pre-forecast

Ready to pursue this opportunity?

Start your free trial to track this contract, build proposals with AI assistance, and manage your pipeline.

Organization & Contact Information

Show more
AgencyDepartment Of Health And Human Services → National Institutes Of Health Nida
ContactsNo contacts available
OfficeN/A
Organization / Agency
Department Of Health And Human Services → National Institutes Of Health Nida
View Agency Profile
Office AddressN/A
ContactsNo contact information available

Full Description

Show more
Idc vehicle 75N95022D00017 ordering period ends 2027-09-04T00:00:00.000Z. 0 active task orders valued at $0.
Nida data, statistics, and clinical trial support center. September 5, 2022 to september 4, 2027. N01da-22-2253. Original Solicitation: 75N95022D00009 IDV Ceiling: $44,313,082 Set-Aside: No set aside used. Contracting Office: National Institutes Of Health Nida Agencies: Department of Health and Human Services Classification: full-recompete (Confidence: high - 85/100)
Top task orders by value: - DSC MANAGEMENT AND SUPPORT. MARCH 1, 2025 TO FEBRUARY 28, 2026. N01DA-22-2253. TASK ORDER NO. 75N95025F00001 (TO25). ($1,848,495.95) - THE EMMES COMPANY, LLC - DATA AND STATISTICAL ANALYSIS FOR GLP-1 AS AN ADJUNCT TO BUPRENORPHINE. MAY 21, 2025 - FEBRUARY 29, 2028. N01DA-22-2253. TASK ORDER NO. 75N95025F00002 (TO26). ($1,397,874.58) - THE EMMES COMPANY, LLC - CRAFT. SEPTEMBER 15, 2023 - MARCH 31, 2025. N01DA-22-2253. TASK ORDER NO. 75N95023F00011 (TO15). ($799,919) - THE EMMES COMPANY, LLC - SECONDARY ANALYSIS. SEPTEMBER 15, 2023 - SEPTEMBER 14, 2026. N01DA-22-2253. TASK ORDER NO. 75N95023F00012 (TO16) ($754,669) - THE EMMES COMPANY, LLC - PHARMACIST-INTEGRATED MODEL OF MEDICATION TREATMENT FOR OPIOID USE DISORDER. 12/01/2023 - 03/31/2025. N01DA-22-2253. TASK ORDER NO. 75N95024F00001 (TO17). ($374,923) - THE EMMES COMPANY, LLC

Similar Contracts

Same NAICS industry code

More opportunities from Department Of Health And Human Services → National Institutes Of Health Nida

Same awarding agency

NAICS: 541715
SBIR / STTR
NIH Small Business Technology Transfer Grant (Parent STTR [R41/R42] Clinical Trial Optional)
Solicitation # PA-27-102
This solicitation supports Small Business Technology Transfer (STTR) grants through the National Institutes of Health to fund research and development projects that advance innovative technologies with potential for commercialization, requiring a formal collaboration between a U.S.-owned small business and a nonprofit research institution. The award is made solely to the small business, regardless of where the principal investigator is employed, and projects must align with the missions of NIH, CDC, or FDA components. Funding is available for Phase I, Phase II, Direct to Phase II, and Fast-Track applications, with Fast-Track allowing combined Phase I and II review to streamline the process. Direct to Phase II is an option for businesses that have already demonstrated technical merit without prior Phase I funding, provided the application is submitted as a new proposal, not a renewal. Only one Phase II award is permitted per Phase I project, and Phase IIB Strategic Breakthrough applications must go through a separate solicitation. Applications must focus on feasibility or R&D that supports public health goals and are subject to restrictions on clinical trials, which are not permitted under this NOFO if exclusively aligned with specific NIH institutes including NIAID, NIAMS, NIDCR, NIDDK, NIMHD, NCATS, and ORIP. The funding opportunity is part of the broader SBIR/STTR mandate, which requires NIH to set aside 0.45% of its extramural budget for STTR, ensuring support for small businesses with fewer than 500 employees. Applicants are encouraged to consult with program staff prior to submission to ensure alignment with funding priorities and to use the Assignment Request Form to suggest an appropriate awarding component, though such identification is not mandatory. The solicitation closes on August 5, 2026, and information on program details, priorities, and frequently asked questions is available through the NIH Seed Fund portal and related government strategies including the Make Our Children Healthy Again initiative.
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

POSTED

3 months ago

DEADLINE

in 7 months
View Details
NAICS: 541715
SBIR / STTR
NIH, CDC and FDA Small Business Innovation Research Grant (Parent SBIR [R43/R44] Clinical Trial Optional)
Solicitation # PA-27-100
This funding opportunity supports U.S. small businesses in advancing early-stage research and development toward commercialization through the SBIR program, administered by the National Institutes of Health, Centers for Disease Control and Prevention, and Food and Drug Administration. Eligible small businesses must be U.S.-owned and operated with fewer than 500 employees and are expected to lead the majority of the technical effort, with the principal investigator primarily employed by the business. The program offers Phase I grants to establish technical feasibility, Phase II grants to advance development toward market readiness, and two special pathways: Direct to Phase II for projects with prior proof of concept but no prior Phase I award, and Fast-Track for combined Phase I and Phase II submissions reviewed concurrently to accelerate progress. All awards are granted to the small business, and commercialization must be pursued using non-SBIR funds after Phase II. The scientific scope must align with the missions of participating NIH, CDC, or FDA components, focusing on health improvement and public health innovation, with applicants encouraged to consult specific institute priorities and the White House’s Make Our Children Healthy Again Strategy. While clinical trials are permitted, they are explicitly excluded if the application aligns solely with certain NIH institutes or all FDA centers, making alignment critical for responsiveness. Applications must be submitted through the designated portal by the deadline, and while applicants are not required to specify an awarding component during submission, consultation with program staff beforehand is strongly advised to ensure proper alignment. The solicitation operates under a complete small business set-aside mandate and is open to new applications only, with no renewals accepted for Direct to Phase II submissions.
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

POSTED

3 months ago

DEADLINE

in 7 months
View Details
NAICS: 541715
SBIR / STTR
SBIR/STTR Commercialization Readiness Pilot (CRP) Program (Parent SB1 Clinical Trial Optional)
Solicitation # PAR-27-098
The Commercialization Readiness Pilot (CRP) program, issued under PAR-27-098, provides late-stage research and development funding and technical assistance to U.S. small business concerns that have previously received an NIH SBIR or STTR Phase II award or a Phase IIB Strategic Breakthrough award. This initiative is designed to bridge the gap between Phase II completion and full commercialization by supporting activities that require significant outsourcing, such as regulatory strategy, intellectual property development, manufacturing optimization, pre-clinical product development, and clinical trials—though not all NIH institutes accept clinical trial proposals. The program permits substantial outsourcing to contract research organizations but requires the small business to maintain active oversight and management of all scientific, financial, and administrative aspects of the work, with justified budget allocations reflecting this role. CRP funding cannot cover FDA filing fees or include separate Technical and Business Assistance (TABA) funds. Eligible applicants must be small business concerns under 500 employees meeting SBA size standards, and proposals must align with the mission of participating NIH components. The solicitation explicitly excludes applications that propose clinical trials solely aligned with certain NIH institutes, including NHLBI, NIAID, NIDDK, and others listed, which do not accept such trials under this program. Applications are limited to Type 1 new submissions, and prior Phase II funding is mandatory for eligibility. Applicants are strongly encouraged to consult with NIH program staff before submitting to ensure alignment with the most appropriate funding mechanism, as the Phase IIB Strategic Breakthrough program (PA-27-101) may be better suited for some projects with matching fund requirements. The solicitation is active through August 5, 2026, under a total small business set-aside, and further details are available through the NIH SBIR/STTR portal.
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

POSTED

3 months ago

DEADLINE

in 7 months
View Details
Vehicle Recompete: Idc 75N95022D00017 | CLEATUS